Timothy Na Archampong1,2, Ceejay L Boyce3, Margaret Lartey1,2, Kwamena W Sagoe4, Adjoa Obo-Akwa1, Ernest Kenu2,5, Jason T Blackard3, Awewura Kwara6,7. 1. Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. 2. Korle-Bu Teaching Hospital, Accra, Ghana. 3. Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 4. Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. 5. School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana. 6. Warren Alpert Medical School of Brown University, Providence, RI, USA. 7. The Miriam Hospital, Providence, RI, USA.
Abstract
BACKGROUND: The presence of HBV resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV-coinfected patients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected Ghanaian patients with detectable HBV viraemia. METHODS: HBV-HIV-coinfected patients who were ART-naive or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study. Demographic and clinical data were collected and HBV DNA quantified. Partial HBV sequences were amplified by PCR and sequenced bi-directionally to obtain a 2.1-2.2 kb fragment for phylogenetic analysis of HBV genotypes and evaluation of drug resistance mutations. RESULTS: Of the 100 HBV-HIV-coinfected study patients, 75 were successfully PCR-amplified, and 63 were successfully sequenced. Of these 63 patients, 27 (42.9%) were ART-experienced and 58 (92.1%) had HBV genotype E. No resistance mutations were observed in the 36 ART-naive patients, while 21 (77.8%) of 27 treatment-experienced patients had resistance mutations. All patients with resistance mutations had no tenofovir in their regimens, and 80% of them had HIV RNA <40 copies/ml. The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173L, rtL180M and rtM204V mutations. CONCLUSIONS: A high proportion of HBV-HIV-coinfected patients with detectable viraemia on 3TC-containing ART had resistance mutations despite good ART adherence as determined by HIV RNA suppression. This study emphasizes the need for dual therapy as part of a fully suppressive ART in all HBV-HIV-coinfected patients in Ghana.
BACKGROUND: The presence of HBV resistance mutations upon initiation or during antiretroviral therapy (ART) in HIV-coinfectedpatients is an important determinant of treatment response. The main objective of the study was to determine the prevalence of HBV resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected Ghanaian patients with detectable HBV viraemia. METHODS:HBV-HIV-coinfectedpatients who were ART-naive or had received at least 9 months of lamivudine (3TC)-containing ART were enrolled in a cross-sectional study. Demographic and clinical data were collected and HBV DNA quantified. Partial HBV sequences were amplified by PCR and sequenced bi-directionally to obtain a 2.1-2.2 kb fragment for phylogenetic analysis of HBV genotypes and evaluation of drug resistance mutations. RESULTS: Of the 100 HBV-HIV-coinfected study patients, 75 were successfully PCR-amplified, and 63 were successfully sequenced. Of these 63 patients, 27 (42.9%) were ART-experienced and 58 (92.1%) had HBV genotype E. No resistance mutations were observed in the 36 ART-naive patients, while 21 (77.8%) of 27 treatment-experienced patients had resistance mutations. All patients with resistance mutations had no tenofovir in their regimens, and 80% of them had HIV RNA <40 copies/ml. The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173L, rtL180M and rtM204V mutations. CONCLUSIONS: A high proportion of HBV-HIV-coinfectedpatients with detectable viraemia on 3TC-containing ART had resistance mutations despite good ART adherence as determined by HIV RNA suppression. This study emphasizes the need for dual therapy as part of a fully suppressive ART in all HBV-HIV-coinfectedpatients in Ghana.
Authors: E M Yoshida; A Ramji; S R Erb; J E Davis; U P Steinbrecher; C H Sherlock; C H Scudamore; S W Chung; M Williams; K S Gutfreund Journal: Liver Date: 2000-10
Authors: S Seddigh-Tonekaboni; J A Waters; S Jeffers; R Gehrke; B Ofenloch; A Horsch; G Hess; H C Thomas; P Karayiannis Journal: J Med Virol Date: 2000-02 Impact factor: 2.327
Authors: Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos Journal: Int J Biochem Cell Biol Date: 2012-04-16 Impact factor: 5.085
Authors: S Seddigh-Tonekaboni; W L Lim; B Young; J L Hou; J Waters; K X Luo; H C Thomas; P Karayiannis Journal: J Viral Hepat Date: 2001-03 Impact factor: 3.728
Authors: M K Jain; L Comanor; C White; P Kipnis; C Elkin; K Leung; A Ocampo; N Attar; P Keiser; W M Lee Journal: J Viral Hepat Date: 2007-03 Impact factor: 3.728
Authors: Alexander J Stockdale; Richard Odame Phillips; Apostolos Beloukas; Lambert Tetteh Appiah; David Chadwick; Sanjay Bhagani; Laura Bonnett; Fred Stephen Sarfo; Geoffrey Dusheiko; Anna Maria Geretti Journal: Clin Infect Dis Date: 2015-05-28 Impact factor: 9.079
Authors: Ceejay L Boyce; Stephaney Willis; Timothy N A Archampong; Margaret Lartey; Kwamena W Sagoe; Adjoa Obo-Akwa; Ernest Kenu; Awewura Kwara; Jason T Blackard Journal: Virus Genes Date: 2019-07-25 Impact factor: 2.332